The results described here support further development of A03 as a first-in-class ApoE4-targeted therapeutic candidate for MCI/AD that increases brain SirT1 levels in the presence of ApoE4 and has the potential to halt progression of AD-like pathology. Here, APOE is linked to Alzheimer disease.